Loading...
Loading...
Radiopharm Theranostics Ltd
Radiopharm Theranostics Ltd. Spoken Alpha tracks RDPTF's earnings calls, guidance changes, and executive accountability over time.
Spoken Alpha tracks RDPTF's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Misses consensus 10/10 quarters
SampleRepeated misses without a guidance reset suggest management is structurally optimistic relative to operating reality. Track whether next-quarter guidance is being benchmarked off the prior miss or the prior plan.
Missed in 4 of the last 4 quarters
SampleRecent misses matter more than long-window beat rate — the trailing 12 months drives the analyst model and the next-print bar.
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for RDPTF.
curl https://api.spokenalpha.com/v1/companies/RDPTF| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $3.17 | $4.00 | -20.8% | +1.3% | +3.3% |
| Q4 FY2026 | $3.25 | $4.08 | -20.3% | -0.5% | +0.9% |
| Q3 FY2026 | $3.69 | $4.00 | -7.7% | +0.8% | +0.9% |
| Q2 FY2026 | $3.30 | $3.94 | -16.2% | -1.3% | +0.3% |
| Q1 FY2025 | $3.17 | $3.98 | -20.4% | -5.1% | -5.2% |
| Q4 FY2025 | $3.63 | $4.01 | -9.6% | +4.4% | +7.3% |
| Q3 FY2025 | $3.85 | $4.12 | -6.6% | -5.5% | -4.1% |
| Q2 FY2025 | $3.28 | $4.03 | -18.6% | -7.4% | -5.7% |
| Q1 FY2024 | $3.73 | $4.02 | -7.2% | 0.0% | -1.8% |
| Q4 FY2024 | $3.37 | $3.98 | -15.3% | +3.2% | +4.5% |